Ramius' Hostile Bid For Cypress Bioscience Has Unusual Twist
This article was originally published in The Pink Sheet Daily
Executive Summary
The hedge fund operator offers $154 million after Cypress' unpopular licensing of an anti-psychotic drug. But Ramius might want to share the upside on the drug after all.